16 completed, 15 unknown, 9 recruiting, 8 terminated. 31 Phase 2, 17 Phase 1, 9 Phase 3, 1 Phase 4.
Follow 1-dodecylpyridoxal: new trials by email Literature Review of 1-dodecylpyridoxal trials Research Report on 1-dodecylpyridoxal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Genmab | 688 | 2026-08-28 | 2026-10-07 |
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer | Phase 2 / Phase 3 | Active not recruiting | Novita Pharmaceuticals, Inc. | 380 | 2025-12-29 | 2026-03-09 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 297 | 2025-05-28 | 2026-09-14 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-21 |
| APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST APG -2449, PLD - Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 90 | 2024-12-17 | 2026-07-21 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 860 | 2024-02-27 | 2026-07-28 |
| APX005M in Patients With Recurrent Ovarian Cancer APX005M - Ovarian Cancer | Phase 2 | Withdrawn | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2023-09-07 | 2023-09-11 | |
| Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer pegylated liposomal doxorubicin - Ovarian Cancer | Unknown | Fudan University | 20 | 2023-08-01 | 2023-08-04 | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) PLD, Oxaliplatin, Capecitabine - Gastric Cancer | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 38 | 2022-09-05 | 2023-03-09 |
| Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Shattuck Labs, Inc. | 86 | 2022-08-18 | 2025-12-23 |
| Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD) - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Pfizer | 10 | 2022-08-01 | 2024-11-19 |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. TILT-123, pembrolizumab, pegylated liposomal doxorubicin - Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | TILT Biotherapeutics Ltd. | 29 | 2022-05-17 | 2026-05-05 |
| Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD Trabectedin and PLD - Ovarian Cancer | Completed | Grupo Español de Investigación en Cáncer de Ovario | 43 | 2021-10-21 | 2023-05-24 | |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC SG001, Doxorubicin hydrochloride liposome injection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 126 | 2021-09-01 | 2021-07-30 |
| ATG-010(Selinexor) in Combination With Chemotherapy in RRMM Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin - Multiple Myeloma | Phase 2 | Unknown | Chunyan Sun, MD | 50 | 2021-05-21 | 2023-12-06 |
| Reprab Study: PLD + Trabectedin Rechallenge PLD and Trabectedin rechallenge - Relapsed Ovarian Cancer | Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 64 | 2020-10-01 | 2021-08-09 |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer IN10018 in combination with PLD - Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 150 | 2020-07-27 | 2026-05-04 |
Showing 20 of 52. Sign in to see all of them.
Ovarian Neoplasms (23) · Fallopian Tube Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Ovarian Epithelial (6) · Multiple Myeloma (4) · Lymphoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Melanoma (2) · Stomach Neoplasms (2) · Adenoviridae Infections (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cardiotoxicity (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (3) · Fudan University (3) · AGO Research GmbH (2) · AstraZeneca (2) · Boehringer Ingelheim (2) · Grupo Español de Investigación en Cáncer de Ovario (2) · InxMed (Shanghai) Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · Oncotherapeutics (2) · Pfizer (2) · Amgen (1) · Ascentage Pharma Group Inc. (1) · Atreca, Inc. (1) · Beth Israel Deaconess Medical Center (1) · Celgene (1)
United States (24) · China (16) · Canada (9) · Spain (9) · United Kingdom (9) · France (7) · South Korea (6) · Taiwan (6) · Australia (5) · Germany (5) · Italy (5) · Poland (5) · Belgium (4) · Japan (4) · Switzerland (4)
James R Berenson, MD (2) · Bradley J Monk, MD (1) · Chunyan Sun, M.D., Ph.D (1) · Dr Timothy Yap (1) · Felix Hilpert, MD, PhD (1) · Francine Foss, MD (1) · George Coukos, MD, PhD (1) · Huang Jian, Dr (1)
PMID 37407274, PMID 37185961, PMID 22056854, PMID 29401246, PMID 31851518, PMID 31912673, PMID 32305099, PMID 34143970, PMID 34329939, PMID 34645648, PMID 35771546, PMID 36239473, PMID 37082579, PMID 37279780, PMID 37665777, PMID 39506856, PMID 40504550, PMID 41566775, PMID 41951722
2015 (2), 2009 (1), 2016 (1), 2018 (1), 2025 (1)